Table III.

 Patients With Treatment‐Emergent Adverse Events Reported in ≥2% of Patients by Treatment Group (Safety Population)

	Sumatriptan/Naproxen Sodium (n=127)	Sumatriptan (n=120)	Naproxen (n=127)
Any adverse event	46 (36)	46 (38)	37 (29)
Adverse events in ≥2% of patients	20 (16)	29 (24)	18 (14)
Nasopharyngitis	4 (3)	6 (5)	5 (4)
Urinary tract infection	1 (<1)	6 (5)	3 (2)
Sinusitis	3 (2)	2 (2)	1 (<1)
Upper respiratory tract infection	0 (0)	5 (4)	1 (<1)
Dizziness	5 (4)	5 (4)	1 (<1)
Somnolence	2 (2)	3 (3)	2 (2)
Back pain	2 (2)	3 (3)	2 (2)
Neck pain	2 (2)	4 (3)	0 (0)
Nausea	4 (3)	2 (2)	1 (<1)
Seasonal allergy	3 (2)	1 (<1)	3 (2)
Sinus congestion	0 (0)	3 (3)	1 (<1)

Values are expressed as number (percentage).